137 related articles for article (PubMed ID: 12016395)
21. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models.
Shim JH; Lee HC; Kim SO; Shin YM; Kim KM; Lim YS; Suh DJ
Radiology; 2012 Feb; 262(2):708-18. PubMed ID: 22187634
[TBL] [Abstract][Full Text] [Related]
22. Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria.
Suzuki C; Torkzad MR; Jacobsson H; Aström G; Sundin A; Hatschek T; Fujii H; Blomqvist L
Acta Oncol; 2010 May; 49(4):509-14. PubMed ID: 20397778
[TBL] [Abstract][Full Text] [Related]
23. The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database.
Litière S; de Vries EGE; Seymour L; Sargent D; Shankar L; Bogaerts J;
Eur J Cancer; 2014 Jul; 50(10):1847-1853. PubMed ID: 24726734
[TBL] [Abstract][Full Text] [Related]
24. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K
Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031
[TBL] [Abstract][Full Text] [Related]
25. Discrepancy in the assessment of tumor response in patients with pancreatic cancer: WHO versus RECIST criteria.
Ahn SH; Garewal HS; Dragovich T
J BUON; 2008; 13(3):359-62. PubMed ID: 18979550
[TBL] [Abstract][Full Text] [Related]
26. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?
Gehan EA; Tefft MC
J Natl Cancer Inst; 2000 Feb; 92(3):179-81. PubMed ID: 10655425
[No Abstract] [Full Text] [Related]
27. Improving accuracy in reporting CT scans of oncology patients: assessing the effect of education and feedback interventions on the application of the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
Andoh H; McNulty NJ; Lewis PJ
Acad Radiol; 2013 Mar; 20(3):351-7. PubMed ID: 23452481
[TBL] [Abstract][Full Text] [Related]
28. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
Sonpavde G; Pond GR; Templeton AJ; Fandi A; Tombal B; Rosenthal M; Armstrong AJ; Petrylak DP
Eur Urol; 2016 Jun; 69(6):980-3. PubMed ID: 26497922
[TBL] [Abstract][Full Text] [Related]
29. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.
van Klaveren RJ; Aerts JG; de Bruin H; Giaccone G; Manegold C; van Meerbeeck JP
Lung Cancer; 2004 Jan; 43(1):63-9. PubMed ID: 14698538
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
Iizumi S; Shimoi T; Tsushita N; Bun S; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
BMC Cancer; 2017 Dec; 17(1):819. PubMed ID: 29202787
[TBL] [Abstract][Full Text] [Related]
31. Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma.
Sager S; Akgün E; Uslu-Beşli L; Asa S; Akovali B; Sahin O; Yeyin N; Demir M; Abuqbeitah M; Gülsen F; Sayman H; Sönmezoglu K
Nucl Med Commun; 2019 May; 40(5):461-468. PubMed ID: 30896544
[TBL] [Abstract][Full Text] [Related]
32. Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy.
Barnacle AM; McHugh K
Pediatr Blood Cancer; 2006 Feb; 46(2):127-34. PubMed ID: 16231313
[TBL] [Abstract][Full Text] [Related]
33. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
[TBL] [Abstract][Full Text] [Related]
34. Selection of response criteria for clinical trials of sarcoma treatment.
Schuetze SM; Baker LH; Benjamin RS; Canetta R
Oncologist; 2008; 13 Suppl 2():32-40. PubMed ID: 18434637
[TBL] [Abstract][Full Text] [Related]
35. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
36. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.
Kobayashi T; Ichiba T; Sakuyama T; Arakawa Y; Nagasaki E; Aiba K; Nogi H; Kawase K; Takeyama H; Toriumi Y; Uchida K; Kobayashi M; Kanehira C; Suzuki M; Ando N; Natori K; Kuraishi Y
Breast Cancer; 2012 Jul; 19(3):218-37. PubMed ID: 22532161
[TBL] [Abstract][Full Text] [Related]
37. Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma.
Guenther LM; Rowe RG; Acharya PT; Swenson DW; Meyer SC; Clinton CM; Guo D; Sridharan M; London WB; Grier HE; Ecklund K; Janeway KA
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29251406
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011.
Kurebayashi J; Miyoshi Y; Ishikawa T; Saji S; Sugie T; Suzuki T; Takahashi S; Nozaki M; Yamashita H; Tokuda Y; Nakamura S
Breast Cancer; 2015 May; 22(3):235-44. PubMed ID: 25758809
[TBL] [Abstract][Full Text] [Related]
39. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Lencioni R; Llovet JM
Semin Liver Dis; 2010 Feb; 30(1):52-60. PubMed ID: 20175033
[TBL] [Abstract][Full Text] [Related]
40. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Nielsen D; Jensen BV; Hendel HW
J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
